United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride - headache, reading difficulty, poor memory • for the temporary relief of symptoms including: • headache • reading difficulty • poor memory these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. clinical studies have shown that when dopamine hcl is administered before urine flow has diminished to levels of approximately 0.3 ml/minute, prognosis is more favorable. nevertheless, in a number of oliguric or anuric patients, administration of dopamine hcl has resulted in an increase in urine flow, which in some cases reached normal levels. dopamine hcl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. it should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. low cardiac output – increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. increase in cardiac output has been associated with either static or decreased systemic vascular resistance (svr). static or decreased svr associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension – hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine hcl which have little effect on svr. at high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished svr. as in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. therefore, it is suggested that the physician administer dopamine hcl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. dopamine hcl should not be used in patients with pheochromocytoma. dopamine hcl should not be administered to patients with uncorrected tachyarrhythmias or ventricular fibrillation.

Israel - English - Ministry of Health

medic trim healthcare ltd - dopamine hydrochloride - solution for infusion - dopamine hydrochloride 200 mg / 5 ml - dopamine - to correct hemodynamic imbalances associated with myocardial infarction trauma septic shock and cardiac surgery. dopamine hydrochloride is used in the treatment of : 1. shock unresponsive to replacement of fluid loss and especially where renal function is impaired. 2. to correct haemodynamic imbalances associated with myocardial infarction trauma septic shock and cardiac surgery. 3. it is also used in the management of chtonic refractory congestive heart failure.

Malta - English - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - dopamine hydrochloride - concentrate for solution for infusion - dopamine hydrochloride 40 mg/ml - cardiac therapy

United States - English - NLM (National Library of Medicine)

hf acquisition co. llc, dba health first - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hcl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hcl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hcl, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hcl. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. clinical studies have shown that when dopamine hcl is administered before urine flow has diminished to levels of approximately 0.3 ml/minute, prognosis is more favorable. nevertheless, in a number of oliguric or anuric patients, administration of dopamine hcl has resulted in an increase in urine flow, which in some cases reached normal levels. dopamine hcl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. it should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. low cardiac output – increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. increase in cardiac output has been associated with either static or decreased systemic vascular resistance (svr). static or decreased svr associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. in many instances the renal fraction of the total cardiac output has been found to increase. increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. hypotension – hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine hcl which have little effect on svr. at high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished svr. as in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. therefore, it is suggested that the physician administer dopamine hcl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. dopamine hcl should not be used in patients with pheochromocytoma. dopamine hcl should not be administered to patients with uncorrected tachyarrhythmias or ventricular fibrillation.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dopamine hydrochloride 1600 mg/ml - solution for infusion - 1600 mg/ml - active: dopamine hydrochloride 1600 mg/ml excipient: glucose monohydrate hydrochloric acid sodium bisulfite water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dopamine hydrochloride 3200 mg/ml - solution for infusion - 3200 mg/ml - active: dopamine hydrochloride 3200 mg/ml excipient: glucose monohydrate hydrochloric acid sodium bisulfite water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dopamine hydrochloride 6400 mg/ml - solution for infusion - 6400 mg/ml - active: dopamine hydrochloride 6400 mg/ml excipient: glucose monohydrate hydrochloric acid sodium bisulfite water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dopamine hydrochloride 800 mg/ml - solution for infusion - 800 mg/ml - active: dopamine hydrochloride 800 mg/ml excipient: glucose monohydrate hydrochloric acid sodium bisulfite water for injection